Abstract:The amyloid β-peptide (Aβ) of Alzheimer's disease (AD) is generated by proteolysis within the transmembrane domain (TMD) of a C-terminal fragment of the amyloid β protein-precursor (APP CTFβ) by the γ-secretase complex. This processing produces Aβ ranging from 38 to 49 residues in length. Evidence suggests that this spectrum of Aβ peptides is the result of successive γ-secretase cleavages, with endoproteolysis first occurring at the ε sites to generate Aβ48 or Aβ49, followed by C-terminal trimming mostly every three residues along two product lines to generate shorter, secreted forms of Aβ: the primary Aβ49-46-43-40 line and a minor Aβ48-45-42-38 line. The major secreted Aβ species are Aβ40 and Aβ42, and an increased proportion of the longer, aggregation-prone Aβ42 compared to Aβ40 is widely thought to be important in AD pathogenesis. We examined TMD substrate determinants of the specificity and efficiency of ε site endoproteolysis and carboxypeptidase trimming of CTFβ by γ-secretase. We determined that the C-terminal negative charge of the intermediate Aβ49 does not play a role in its trimming by γ-secretase. Peptidomimetic probes suggest that γ-secretase has S1', S2', and S3' pockets, through which trimming by tripeptides may be determined. However, deletion of residues around the ε sites demonstrates that a depth of three residues within the TMD is not a determinant of the location of endoproteolytic ε cleavage of CTFβ. We also show that instability of the CTFβ TMD helix near the ε site significantly increases endoproteolysis, and that helical instability near the carboxypeptidase cleavage sites facilitates C-terminal trimming by γ-secretase. In addition, we found that CTFβ dimers are not endoproteolyzed by γ-secretase. These results support a model in which initial interaction of the array of residues along the undimerized single helical TMD of substrates dictates the site of initial ε cleavage and that helix unwinding is essential for both endoproteolysis and carboxypeptidase trimming.

Extracellular interface between APP and Nicastrin regulates Aβ length and response to γ‐secretase modulators

Accumulation of APP C-terminal fragments causes endolysosomal dysfunction through the dysregulation of late endosome to lysosome-ER contact sites

Hydrophilic loop 1 of Presenilin-1 and the APP GxxxG transmembrane motif regulate γ-secretase function in generating Alzheimer-causing Aβ peptides

Enzyme–substrate interface targeting by imidazole‐based γ‐secretase modulators activates γ‐secretase and stabilizes its interaction with APP

Spectrum of gamma-Secretase dysfunction as a unifying predictor of ADAD age at onset across PSEN1, PSEN2 and APP causal genes

Transmembrane Substrate Determinants for Γ-Secretase Processing of APP CTFβ

P4‐687: SUBSTRATE BINDING INHIBITS Γ‐secretase CLEAVAGE OF AMYLOID PRECURSOR PROTEIN

A GPCR/secretase Complex Regulates Β- and Γ-Secretase Specificity for Aβ Production and Contributes to AD Pathogenesis

APP β-CTF triggers cell-autonomous synaptic toxicity independent of Aβ

Nicastrin is Critical for Stability and Trafficking but Not Association of Other Presenilin/γ-Secretase Components*

Differential, dominant activation and inhibition of Notch signalling and APP cleavage by truncations of PSEN1 in human disease

GSAP Regulates Mitochondrial Function Through the Mitochondria-associated ER Membrane in the Pathogenesis of Alzheimer’s Disease

APP and its intracellular domain modulate Alzheimer’s disease risk gene networks in transgenic and porcine models

Substrate check of γ-secretase

Mutations in APP have independent effects on Aβ and CTFγ generation

Construction of Drug Screening Cell Model and Application to New Compounds Interfering Production and Accumulation of Beta-Amyloid by Inhibiting Gamma-Secretase

An internal docking site stabilizes substrate binding to γ-secretase: Analysis by molecular dynamics simulations

GSAP Regulates Lipid Homeostasis and Mitochondrial Function Associated with Alzheimer’s Disease

The Gamma-Secretase Complex: from Structure to Function

Inhibition of Γ-Secretase Activity Reduces Aβ Production, Reduces Oxidative Stress, Increases Mitochondrial Activity and Leads to Reduced Vulnerability to Apoptosis: Implications for the Treatment of Alzheimer's Disease

γ‐Secretase Modulator BPN15606 Reduced Aβ42 and Aβ40 and Countered Alzheimer‐Related Pathologies in a Mouse Model of Down Syndrome